Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Regulatory News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.00
Bid: 10.50
Ask: 11.50
Change: 0.50 (4.76%)
Spread: 1.00 (9.524%)
Open: 10.50
High: 11.00
Low: 10.50
Prev. Close: 10.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Jul 2019 15:12

RNS Number : 1716G
Destiny Pharma PLC
19 July 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

DESTINY PHARMA HOLDINGS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

CANACCORD GENUITY GROUP INC

City and country of registered office (if applicable)

VANCOUVER, CANADA

4. Full name of shareholder(s) (if different from 3.)v

Name

DISCRETIONARY CLIENTS

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

16 JULY 2019

6. Date on which issuer notified (DD/MM/YYYY):

18 JULY 2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

9.9215

9.9215

43,865,195

Position of previous notification (if

applicable)

10.2199

10.2199

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BDHSP575

4,352,070

9.9215

SUBTOTAL 8. A

4,352,070

9.9215

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Canaccord Genuity Group Inc.

9.9215

9.9215

 

Canaccord Genuity Wealth Group Holdings Limited

9.9215

9.9215

 

Canaccord Genuity Wealth Group Holdings (Jersey) Limited

9.9215

9.9215

 

Canaccord Genuity Wealth Group Limited

9.9215

9.9215

 

Hargreave Hale Ltd

9.9215

9.9215

 

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

 

 

 

 

Place of completion

BLACKPOOL, ENGLAND

Date of completion

18 JULY 2019

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLEALXNFENNEFF
Date   Source Headline
22nd Dec 20229:05 amRNSSecond Price Monitoring Extn
22nd Dec 20229:00 amRNSPrice Monitoring Extension
22nd Dec 20227:00 amRNSYear End Trading Update
7th Dec 20227:00 amRNSFDA/CDC highlight need for infection preventions
7th Dec 20227:00 amRNSXF-73 Nasal final Phase 3 development plans
2nd Dec 20222:48 pmRNSDirector Disclosure
23rd Nov 20227:00 amRNSAppointment of Corporate Broker
21st Nov 20222:20 pmEQSDestiny Pharma PLC 'leads the world' in new approach to preventing hospital infections
18th Nov 20221:16 pmRNSDirector Shareholding Amendment
15th Nov 20227:00 amRNSXF-73 advances to clinically enabling safety study
31st Oct 202211:06 amRNSSecond Price Monitoring Extn
31st Oct 202211:01 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSNotice of R&D Update Meeting
8th Sep 20227:00 amRNSInterim results for six months ended 30 June 2022
7th Sep 20227:03 amRNSPresenting at HC Wainwright Investment Conference
7th Sep 20227:01 amRNSPositive update from EMA on NTCD-M3 Phase 3 plans
5th Sep 20222:15 pmRNSExpiry of Share Options
22nd Aug 20227:00 amRNSNotice of Interim Results
28th Jul 20227:00 amRNSChair’s Investor Update
26th Jul 20227:00 amRNSPublication of new data on NTCD-M3
19th Jul 20227:00 amRNSPositive update from US FDA on XF-73 Phase 3
12th Jul 20227:00 amRNSGrant from the Cystic Fibrosis Foundation
7th Jul 20227:00 amRNSPublication of XF-73 drug synergy data
5th Jul 20227:00 amRNSNew XF-73 research programme
8th Jun 20227:00 amRNSGrant of share options
27th May 202211:56 amRNSResult of Annual General Meeting & Strategy Update
26th May 20227:00 amRNSBoard Changes
12th May 20227:00 amRNSLandmark NTCD-M3 data to be presented at Anaerobe
3rd May 20227:00 amRNSDestiny Pharma appoints Dr Yuri Martina as CMO
27th Apr 20223:34 pmRNSPosting of Annual Report and Notice of AGM
26th Apr 20223:30 pmRNSDirector/PDMR Shareholding
12th Apr 20227:00 amRNSAudited results for year ended 31 December 2021
4th Apr 20222:45 pmRNSNotice of Results
4th Apr 20222:37 pmRNSNotification of Major Holdings
31st Mar 20227:00 amRNSTo present data at ECCMID Congress
28th Mar 202211:30 amRNSResult of General Meeting and Total Voting Rights
25th Mar 20227:00 amRNSResult of Open Offer
22nd Mar 202210:30 amRNSExercise of Options and Total Voting Rights
8th Mar 202212:30 pmRNSFundraising
8th Feb 20227:00 amRNSPositive feedback from EMA on XF-73 Nasal gel Ph 3
1st Feb 20224:11 pmRNSExercise of Options and Total Voting Rights
1st Feb 20227:00 amRNSPositive data in XF-73 Dermal study with NIAID
31st Jan 20222:30 pmRNSExercise of Options and Total Voting Rights
25th Jan 20227:00 amRNSGrant of share options
24th Jan 20227:00 amRNSClinical and commercial opportunity of NTCD-M3
21st Jan 20227:15 amRNSDestiny Pharma Lancet Report
17th Jan 20227:00 amRNSStrategy/Company/Ops Update
21st Dec 20214:35 pmRNSExercise of Options and Total Voting Rights
17th Dec 20219:46 amRNSGrant of share options
15th Nov 20212:26 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.